Table 31.
Country | N | MDR patterns of isolates resistant to both CIP and CTX (number of isolates) | Resistant to both CIP and CTX, applying ECOFFs | Resistant to both CIP and CTX, applying CBPs | ||
---|---|---|---|---|---|---|
N | % Res | N | % Res | |||
Austria | 163 | CTX‐CAZ‐CIP‐AMP‐NAL(1) | 2 | 1.2 | 1 | 0.6 |
CTX‐CAZ‐CIP‐AMP‐TET(1) | ||||||
Cyprus | 55 | CHL‐CTX‐CIP‐AMP‐NAL‐SMX‐TET‐TMP(1) | 2 | 3.6 | 1 | 1.8 |
GEN‐CHL‐CTX‐CAZ‐CIP‐TGC‐AMP‐NAL‐SMX‐TET‐TMP(1) | ||||||
Czech Republic | 187 | GEN‐CTX‐CAZ‐CIP‐AMP‐NAL‐SMX‐TET‐TMP(1) | 1 | 0.5 | 1 | 0.5 |
Germany | 212 | CHL‐CTX‐CAZ‐CIP‐AMP‐NAL‐SMX‐TET‐TMP(1) | 1 | 0.5 | 1 | 0.5 |
Greece | 116 | CHL‐CTX‐CAZ‐CIP‐AMP‐SMX‐TET‐TMP(1) | 3 | 2.6 | 0 | 0 |
CTX‐CAZ‐CIP‐AMP‐NAL‐TET(1) | ||||||
CTX‐CAZ‐CIP‐AMP‐SMX‐TET‐TMP(1) | ||||||
Hungary | 170 | CHL‐CTX‐CAZ‐CIP‐AMP‐NAL‐SMX‐TET‐TMP(1) | 2 | 1.2 | 0 | 0 |
CTX‐CAZ‐CIP‐AMP‐NAL‐SMX‐TET‐TMP(1) | ||||||
Portugal | 198 | CHL‐CTX‐CAZ‐CIP‐AMP‐NAL‐SMX‐TET‐TMP(2) | 7 | 3.5 | 6 | 3 |
CHL‐CTX‐CAZ‐CIP‐AMP‐SMX‐TET‐TMP(1) | ||||||
CTX‐CAZ‐CIP‐AMP‐NAL‐SMX‐TET‐TMP(2) | ||||||
CTX‐CAZ‐CIP‐AMP‐NAL‐TET(1) | ||||||
GEN‐CHL‐CTX‐CAZ‐CIP‐AMP‐NAL‐SMX‐TET‐TMP(1) | ||||||
Romania | 399 | CHL‐CTX‐CAZ‐CIP‐AMP‐NAL‐SMX‐TET(1) | 5 | 1.3 | 1 | 0.3 |
CTX‐CAZ‐CIP‐AMP‐NAL‐SMX‐TET‐TMP(1) | ||||||
CTX‐CAZ‐CIP‐AMP‐NAL‐TET‐TMP(1) | ||||||
CTX‐CAZ‐CIP‐AMP‐SMX‐TET(1) | ||||||
GEN‐CHL‐CTX‐CAZ‐CIP‐AMP‐NAL‐SMX‐TET‐TMP(1) | ||||||
Spain | 170 | CHL‐CTX‐CAZ‐CIP‐AMP‐NAL‐SMX‐TET‐TMP(1) | 1 | 0.6 | 1 | 0.6 |
Total (9 MSs) | 1,670 | 24 | 1.4 | 12 | 0.7 |
N: number of isolates tested; CIP: ciprofloxacin; CTX: cefotaxime; ECOFFs: epidemiological cut‐off values; % Res: percentage of resistant isolates; CBPs: clinical breakpoints; CAZ: ceftazidime; NAL: nalidixic acid; AMP: ampicillin; TET: tetracycline; GEN: gentamicin; CHL: chloramphenicol; COL: colistin; SMX: sulfamethoxazole; TMP: trimethoprim; MSs: Member States.